[go: up one dir, main page]

AR116956A1 - GALANINE 2 RECEPTOR AGONISTS - Google Patents

GALANINE 2 RECEPTOR AGONISTS

Info

Publication number
AR116956A1
AR116956A1 ARP190103195A ARP190103195A AR116956A1 AR 116956 A1 AR116956 A1 AR 116956A1 AR P190103195 A ARP190103195 A AR P190103195A AR P190103195 A ARP190103195 A AR P190103195A AR 116956 A1 AR116956 A1 AR 116956A1
Authority
AR
Argentina
Prior art keywords
galanine
receptor agonists
proteins
galanin
gal2
Prior art date
Application number
ARP190103195A
Other languages
Spanish (es)
Original Assignee
Lifearc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifearc filed Critical Lifearc
Publication of AR116956A1 publication Critical patent/AR116956A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a una proteína quimérica que comprende: (i) un fragmento de galanina que consta de los residuos 2-13 de galanina (Gal2-13) o una variante de ella, y (ii) una región Fc así como también una composición farmacéutica que comprende estas proteínas. Estas proteínas son adecuadas para usar en el tratamiento del dolor.This refers to a chimeric protein comprising: (i) a galanin fragment consisting of galanin residues 2-13 (Gal2-13) or a variant thereof, and (ii) an Fc region as well as a pharmaceutical composition comprising these proteins. These proteins are suitable for use in treating pain.

ARP190103195A 2018-11-02 2019-11-01 GALANINE 2 RECEPTOR AGONISTS AR116956A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1817943.2A GB201817943D0 (en) 2018-11-02 2018-11-02 Galanin-2 receptor agonists

Publications (1)

Publication Number Publication Date
AR116956A1 true AR116956A1 (en) 2021-06-30

Family

ID=64655466

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103195A AR116956A1 (en) 2018-11-02 2019-11-01 GALANINE 2 RECEPTOR AGONISTS

Country Status (2)

Country Link
AR (1) AR116956A1 (en)
GB (1) GB201817943D0 (en)

Also Published As

Publication number Publication date
GB201817943D0 (en) 2018-12-19

Similar Documents

Publication Publication Date Title
ECSP19046893A (en) NEW COMPOUNDS AS TRIGONAL PEPTIDIC AGONISTS OF GLP1 / GLUCAGON / GIP RECEPTORS
CO2019002371A2 (en) Adenovirus armed with bispecific t lymphocyte scavenger (bite)
CL2021003477A1 (en) 2,3-dihydroquinazoline compounds as nav1 .8 inhibitors
CL2020002841A1 (en) Rip1 Inhibitor Compounds and Methods for Making and Using The Same
ECSP20020410A (en) ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES OF THE SAME
MX2024013963A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
CO2021010150A2 (en) Irreversible inhibitors of the menin-mll interaction
MX2020009856A (en) RIMEGEPANT FOR CALCITONIN GENE-RELATED PEPTIDE (CGRP)-RELATED DISORDERS.
ECSP23095307A (en) GLP-1 RECEPTOR AGONIST AND COMPOSITION AND USE THEREOF
MX2020008977A (en) Subcutaneous her2 antibody formulations.
CO2020015153A2 (en) Rip1 Inhibitor Compounds and Methods for Making and Using Them
AR122018A1 (en) NKG2D, CD16 AND CLEC12A BINDING PROTEINS
CL2017002527A1 (en) Use of formyl 2 peptide receptor agonists to treat inflammatory eye diseases. (divisional of application n ° 2485-2015).
PE20161170A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING AZD9291
CL2020002574A1 (en) Novel analogs of glp-1
AR067555A1 (en) DERIVATIVE OF INSULINOTROPIC PEPTIDE IN WHICH THE N-TERMINAL AMINO ACID IS MODIFIED
MX2020012273A (en) Protein binding nkg2d, cd16 and a fibroblast activation protein.
MX2017015105A (en) SELECTIVE YY (PYY) PEPTIDE COMPOUNDS AND THEIR USES.
MX376312B (en) Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
CL2017002913A1 (en) Treatment of postbariatric hypoglycemia with exendin (9-39)
MX380531B (en) Peroxisome proliferator-activated receptor (PPAR) agonists, compounds, pharmaceutical compositions, and methods of using the same.
CL2021000924A1 (en) Use of reboxetine for the treatment of narcolepsy
MX2019000235A (en) Human-enzyme mediated depletion of cystine for treating patients with cystinuria.
MX2019001850A (en) Formulations for oral administration of active agents.
AR104173A1 (en) PROTOXIN II VARIANTS AND METHODS OF USE

Legal Events

Date Code Title Description
FB Suspension of granting procedure